Zimbabwe has rejected a substantial US health deal worth 367 million US dollars (272 million pounds) over five years due to the United States' insistence on sensitive data.
The decision became public after a official document dated December was leaked, which showed Head of State Emmerson Mnangagwa believed the agreement was "unbalanced".
A government spokesman has since stated that the US was seeking genetic material for research and commercial purposes but was not willing to share the resulting advantages from any future treatments.
"We are forced to start the challenging and unfortunate task of ending our health assistance in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the United States had furnished more than $1.9bn in health funding to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has urged continued dialogue to secure a deal agreeable to all parties so the nation's vital HIV treatment initiative can proceed.
Wider Background
This rejection comes after a comparable situation in Kenya, where a high court suspended a similar health funding agreement after concerns were filed about the security of citizens' medical information.
Since resuming the presidency recently, US President Donald Trump has drastically cut overseas assistance and shut down the key foreign aid agency.
USAID had overseen aid for the American government, but Trump argued its spending was "inefficient" and his government was pursuing government-to-government agreements to boost openness and accountability.
Based on reports, Sixteen African countries have to date signed similar agreements, constituting more than $18.3bn in new funding.
Details of the Declined Agreement
This assistance for Zimbabwe would have funded "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this collaboration might have yielded extraordinary benefits for Zimbabwean communities, especially the 1.2 million men, women and children presently on HIV treatment through US-supported initiatives," Tremont said.
However, official spokesman Nick Mangwana said the arrangement was "unequal".
"Our nation was requested to share its genetic material and health information indefinitely, without any equivalent promise of access to any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that might result from that shared data," he stated.
"Put simply, our country would provide the raw materials for medical research without any certainty that the end products would be accessible to our citizens should a new health crisis emerge."
Sovereignty and International Frameworks
Mangwana further noted that the American exit from the global health body and its pursuit of bilateral health agreements were undermining systems previously established via the international organization.
The spokesperson gave as an example its Pandemic Benefit-Sharing scheme created to manage future global health emergencies.
"This mechanism is intended to ensure that when a nation contributes its information, the resulting advantages – including vaccines and treatments – are distributed fairly, not commercialised solely by those with the funds to develop them."
These objections over the US deal "should not be misconstrued as opposition to America," he added.
"We welcome further discussions with our US partners on how future co-operation could be designed in a way that respects the sovereignty and interests of each country."
Medical Community Response
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it recognised the government's concerns, but urged that talks should continue since a large portion of the country's Aids initiatives depended on foreign aid.
"If technical issues exist, such as those involving information security or agreement terms, these can often be resolved through technical clarification and negotiated safeguards," it said.
The situation emphasises the ongoing debate between receiving vital foreign assistance and safeguarding local interests in an increasingly data-driven world.